• Pemetrexed: Evidence, Scope, and Limitations

  2026-10-07

  A source-grounded overview of pemetrexed principles, the evidence from malignant mesothelioma research, interpretation boundaries, and key limitations of preclinical findings.

• LY2603618: Redox Context for Chk1 Research

  2026-10-07

  LY2603618 is a selective Chk1 inhibitor for studying checkpoint control, DNA damage, and chemotherapy sensitization. This article adds a redox-and-nucleotide perspective, showing how the 2024 Nature Communications study refines interpretation of Chk1 inhibitor sensitivity in lung cancer models.

• BMP4–GPX4 and Retinal Repair in NMDA Glaucoma

  2026-10-06

  Fang et al. connect BMP4–GPX4 signaling with ferroptosis-related retinal ganglion cell injury and the differentiation performance of transplanted retinal stem cells in an NMDA-based mouse glaucoma model. The study’s main value is its integration of oxidative, iron-dependent cell-death markers with a regenerative transplantation question, although the model remains narrower than human high-intraocular-pressure glaucoma.

• NU7441 (KU-57788): DNA-PK Evidence Guide

  2026-10-06

  NU7441, also called KU-57788, is a vendor-characterized ATP-competitive DNA-PK inhibitor for mechanistic DNA repair research and oncology research. Its biochemical selectivity does not establish cellular or clinical selectivity, and HIV-latency findings provide biological rationale rather than direct proof of NU7441 efficacy.

• PNU 74654: Interpreting Wnt Pathway Inhibition

  2026-10-05

  PNU 74654 is a Wnt signaling pathway inhibitor suited to context-aware studies of β-catenin biology. This article examines how its reported properties relate to the WNT5a/GSK3/β-catenin findings in muscle progenitors, while separating plausible research questions from conclusions the evidence does not support.

• Rapamycin Beyond mTOR: Resistance, Context, Translation

  2026-10-05

  Rapamycin and Sirolimus remain powerful tools for interrogating mTOR biology, but translational value increasingly depends on understanding resistant tumor states, immune suppression, and disease-specific context.

• CHIR-99021 (CT99021) HCl Overview

  2026-10-04

  CHIR-99021 (CT99021) HCl is an APExBIO-listed small-molecule glycogen synthase kinase-3α/β inhibitor for conceptual research in cell signaling and stem-cell biology. No matched paper evidence was provided, so product claims should not be interpreted as independently validated performance.

• Salinomycin in HCC: From Ion Flux to Evidence

  2026-10-03

  Salinomycin is a polyether ionophore antibiotic with reported activity in hepatocellular carcinoma models. This evidence-focused analysis connects ion transport, ABC transporter modulation, Wnt/β-catenin signaling, apoptosis, and animal toxicology without overstating translational relevance.

• SpCas9 mRNA for Transient Genome Editing

  2026-10-02

  SpCas9 mRNA (ARCA, 5mCTP, ψUTP) supports transient CRISPR-Cas9 genome editing without a DNA expression cassette. This guide translates its modified-RNA design into practical workflows for cultured cells, embryos, and delivery studies, with troubleshooting focused on RNA integrity, guide performance, delivery, and assay timing.

• Shenqi Fuzheng, SRC/PI3K/AKT, and Glioma

  2026-10-01

  The 2024 Journal of Ethnopharmacology study combined network pharmacology with cellular and mouse experiments to investigate how Shenqi Fuzheng injection affects glioma proliferation and migration. Its main contribution is the identification and experimental support of SRC/PI3K/AKT signaling as a candidate mechanism, while its design also clarifies which findings remain hypothesis-generating for angiogenesis-focused research.

• Tacrine hydrochloride hydrate Research Workflows

  2026-10-01

  Build reproducible cholinesterase, neuroprotection, and toxicity workflows around Tacrine hydrochloride hydrate, from concentration selection to orthogonal validation. The guide distinguishes benchmark enzyme inhibition from broader Alzheimer’s disease research applications and provides practical troubleshooting for variable potency, precipitation, and cell stress.

• Cy5 TSA Fluorescence System Kit for Spatial Imaging

  2026-09-30

  The Cy5 TSA Fluorescence System Kit strengthens IHC, ICC, and FISH workflows when conventional fluorescence cannot resolve scarce targets. Its localized HRP-driven deposition supports far-red imaging, lower antibody or probe consumption, and practical validation of metastasis-associated markers.

• Amiloride (MK-870) Workflow Guide

  2026-09-30

  Build cleaner ion-transport and receptor-trafficking experiments with Amiloride (MK-870), using reversible pharmacology, matched controls, and time-resolved readouts. The guide translates ENaC, PC2, and uPAR-focused applications into practical workflows for sodium channel research, cystic fibrosis models, hypertension research, and cellular endocytosis modulation.

• NET-DNA, CCDC25, and ILC3 Repair

  2026-09-29

  A 2026 FASEB Journal study identifies NET-derived DNA as an inhibitor of ILC3-mediated intestinal repair in ulcerative colitis models. Its data connect NET-DNA sensing through CCDC25 with reduced IL-22 production, impaired epithelial barrier restoration, and a potential mechanism linking neutrophil activity to delayed mucosal healing.

• Protein Corona Effects on Nanoparticle Function

  2026-09-29

  Elizabeth Voke’s UC Berkeley dissertation develops a label-free, quantitative proteomics workflow for characterizing protein coronas on lipid nanoparticles in human plasma. Its central functional finding is that greater cellular uptake does not necessarily produce greater mRNA expression, highlighting lysosomal trafficking as an important variable in nanoparticle delivery studies.

8107 records 1/541 page Next 12345 下5页 Last page